Despite expression of immunogenic polypeptides, tumors escape immune surveillance by
engaging T cell checkpoint regulators and expanding Tregs, among other mechanisms …

In contrast to its inhibitory effects on many cells, IL10 activates CD8+ tumor-infiltrating
lymphocytes (TIL) and enhances their antitumor activity. However, CD8+ TILs do not …

New data from Wang and colleagues show that complement C3 suppresses the function of
CD8+ tumor-infiltrating T cells by inhibiting IL10 production, and targeting the complement …

Complement aids in the construction of an immunosuppressive tumor microenvironment.
Tumor cell–derived C3 has been previously reported, but whether and how it acts on …

The CD2–CD58 recognition system promotes adhesion and signaling and counters
exhaustion in human T cells. We found that CD2 localized to the outer edge of the mature …

Understanding at the molecular level of the cell biology of tumors has led to significant
treatment advances in the past. Despite such advances however, development of therapy …

Limitations of checkpoint inhibitor cancer immunotherapy include induction of autoimmune
syndromes and resistance of many cancers. Since CD318, a novel CD6 ligand, is …

Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …

Modulation of antitumor immune responses by targeting immune checkpoint regulators has
been proven successful in the treatment of many different tumors. Recent evidence shows …

The clinical benefits that have been achieved for a group of cancer patients with metastatic
disease on checkpoint inhibitor therapy have kindled intense interest in understanding …